#United States #New York #Elysium Health #NAD+ #BASIS

Exploring Elysium Health's Groundbreaking Study on Menopause and NAD+

In a recent development in women's health research, Elysium Health, a pioneering company in longevity science, has published compelling findings regarding the effects of their flagship product, Basis, on menopausal symptoms and the metabolism of NAD+. This study, published in the scientific journal Frontiers in Aging, has provided crucial insights into how Basis may serve as a remedy for some of the most challenging symptoms associated with menopause.

Significant Improvements in Menopause Symptoms

The pilot study included 40 women aged 35 and older, of which 32 participants reported experiencing disruptive menopausal symptoms, categorized as the Menopause Symptom (MS) group, while the remaining eight did not face notable symptoms (No-MS group). After a week of taking Basis, those in the MS group noted substantial reductions—over 50%—in the frequency and severity of symptoms like hot flashes, bloating, and sleep disruptions. This finding represents a major breakthrough for women navigating the trials of menopause, indicating that NAD+ metabolism may play a pivotal role in regulating estrogen levels.

Dr. Leonard Guarente, the Chief Scientist at Elysium and a respected authority in aging research, developed Basis. This clinically proven supplement is designed to raise NAD+ levels, which are critical for cellular health and metabolism as we age. Backed by over 20 clinical trials, Basis aims to restore youthfulness at the cellular level, offering hope for healthier aging processes.

Insights into Estrogen Balance

Perhaps even more groundbreaking were the findings related to estrogen balance. The study observed a notable increase in the ratio of estradiol (E2) to estrone (E1), two essential forms of estrogen in women. E2 is typically more active and beneficial during the menopausal transition, while E1 can fluctuate undesirably, leading to various health issues. The restoration of a favorable E2 to E1 ratio illustrates how NAD+ metabolism might influence hormonal health during menopause, suggesting that supporting this metabolic pathway can be crucial for women during this life stage.

Marie Migaud, Ph.D., co-author of the study, recounted her own experience with Basis and its impact on her menopausal symptoms. Encouraged by her results, the research team hypothesized that enhancing NAD+ levels might help maintain a healthier balance between these estrogens. The data collected not only confirmed this hypothesis but also led to the discovery of a new NAD+ metabolite, adding another layer to our understanding of NAD+ functionality and signaling.

Broader Implications and Future Research

The research signifies more than just symptom relief; it indicates a potential paradigm shift in how we view the interconnection between hormonal regulation and cellular metabolism. As noted by Yousin Suh, Ph.D., a newly appointed member of Elysium's Scientific Advisory Board and an expert in reproductive sciences, the findings highlight an essential yet under-researched facet of women's health.

While this pilot study offers promising insights, Elysium Health recognizes that further investigation is necessary. Plans for larger and more rigorous clinical trials are underway, which will aim to deepen our understanding of NAD+ support's role in improving women's health and wellness across different life stages. By combining scientific inquiry with clinical applications, Elysium Health is committed to championing women's health and longevity.

Conclusion

Elysium Health's latest research shines a light on the important relationship between NAD+ metabolism and menopausal symptoms. By showcasing significant improvements in key health markers, it underlines the relevance of targeting cellular aging to enhance overall wellness. As further studies are conducted, Elysium looks forward to translating these findings into real-world solutions that can empower women to live healthier, more vibrant lives during and beyond the menopausal transition.